Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: Evidence from 16,266 patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gu, Xiaobin ^a   Gao, Xianshu ^a   Li, Xiaoying ^a   Qi, Xin ^a   Ma, Mingwei ^a   Qin, Shangbin ^a   Yu, Hao ^a   Sun, Shaoqian ^a   Zhou, Dong ^a   Wang, Wen ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DISEASE FREE SURVIVAL; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; META ANALYSIS; MORTALITY; NEUTROPHIL; PROSTATE TUMOR; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; NEUTROPHILS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84959449665     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22089     Document Type: Article

References (40)

1. Siegel, R. L., Miller, K. D., & Jemal, A. Cancer Statistics, 2015. CA-Cancer J. Clin. 65, 5-29 (2015).
2. Damber, J. E., & Aus, G. Prostate cancer. Lancet. 371, 1710-1721 (2008).
3. Fung, C., Dale, W., & Mohile, S. G. Prostate Cancer in the Elderly Patient. J. Clin. Oncol. 32, 2523-2530 (2014).
4. Gregory, A. D., & Houghton, A. M. Tumor-Associated neutrophils: new targets for cancer therapy. Cancer Res. 71, 2411-2416 (2011).
5. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011).
6. Grivennikov, S. I., Greten, F. R., & Karin, M. Immunity, Inflammation, and Cancer. Cell. 140, 883-899 (2010).
7. Hashimoto, K., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103, 1856-1864 (2005).
8. Gu, L., et al. The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-Analysis. PloS one 10, e0125538, doi: 10.1371/journal.pone.0125538 (2015).
9. Duan, H., et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. World J Gastroenterol. 21, 5591-5597 (2015).
10. Cannon, N. A., et al. Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer. J. Thorac. Oncol. 10, 280-285 (2015).
11. Templeton, A. J., et al. Prognostic role of neutrophil-To-lymphocyte ratio in solid tumors: a systematic review and meta-Analysis. J Natl Cancer Inst. 106, dju124, doi: 10.1093/jnci/dju124 (2014).
12. Nuhn, P., et al. Association of pretreatment neutrophil-To-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 114, E11-E17 (2014).
13. Templeton, A. J., et al. Simple Prognostic Score for Metastatic Castration-Resistant Prostate Cancer With Incorporation of Neutrophil-To-Lymphocyte Ratio. Cancer 120, 3346-3352 (2014).
14. Langsenlehner, T., et al. Validation of the neutrophil-To-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol, 33, 1661-1667 (2015).
15. Linton, A., et al. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 11, 423-430 (2013).
16. Shafique, K., et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 15, 195-201 (2012).
17. van Soest, R. J., et al. Neutrophil-To-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 26, 743-749 (2015).
18. Yao, A., et al. High neutrophil-To-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 22, 827-833 (2015).
19. Sharma, V., et al. The association of preoperative neutrophil to lymphocyte ratio with oncologic outcomes following radical prostatectomy for prostate cancer. J Urol. 193, e55-E56 (2015).
20. Poyet, C., et al. Pretreatment systemic inflamatory response parameters do not predict the outcome in men with prostate cancer undergoing radical prostatectomy. J Urol. 193, e817 (2015).
21. Lorente, D., et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 26, 750-755 (2015).
22. Lee, H., et al. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol. doi: 10.1007/s00345-015-1701-6 (2015).
23. Kwon, Y. S., et al. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin Genitourin Cancer, doi: 10.1016/j.clgc.2015.07.018 (2015).
24. Bahig, H., et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer 15, 594, doi: 10.1186/s12885-015-1599-9 (2015).
25. Sumbul, A. T., et al. Neutrophil-To-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 46, 1531-1535 (2014).
26. Proctor, M. J., et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107, 695-699 (2012).
27. Cho, I. R., et al. Pre-Treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer. 17, 703-710 (2014).
28. Xiao, W. K., et al. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-Analysis. BMC Cancer 14, 10, doi: 10.1186/1471-2407-14-117 (2014).
29. Coussens, L. M., & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
30. Koizumi, K., Hojo, S., Akashi, T., Yasumoto, K., & Saiki, I. Chemokine receptors in cancer metastasis and cancer cell-Derived chemokines in host immune response. Cancer Sci. 98, 1652-1658 (2007).
31. Roxburgh, C. S., & McMillan, D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6, 149-163 (2010).
32. Koh, C. H., et al. Utility of pre-Treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br. J. Cancer 113, 150-158 (2015).
33. Li, M. X., et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-Analysis. Int J Cancer. 134, 2403-2413 (2014).
34. Gu, X. B., Tian, T., Tian, X. J., & Zhang, X. J. Prognostic significance of neutrophil-To-lymphocyte ratio in non-small cell lung cancer: a meta-Analysis. Sci Rep. 5, 12493, doi: 10.1038/srep12493 (2015).
35. Szkandera, J., et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-Tissue sarcoma patients. Br J Cancer. 108, 1677-1683 (2013).
36. Hu, K., Lou, L., Ye, J., & Zhang, S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-Analysis. BMJ open 5, e006404, doi: 10.1136/bmjopen-2014-006404 (2015).
37. Wei, Y., Jiang, Y. Z., & Qian, W. H. Prognostic role of NLR in urinary cancers: a meta-Analysis. PloS one 9, e92079, doi: 10.1371/ journal.pone.0092079 (2014).
38. Ndibe, C., Wang, C. G., & Sonpavde, G. Corticosteroids in the Management of Prostate Cancer: A Critical Review. Curr Treat Options Oncol. 16, 6, doi: 10.1007/s11864-014-0320-6 (2015).
39. Zaragoza, J., et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol, doi: 10.1111/bjd.14155 (2015).
40. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. Practical methods for incorporating summary time-To-Event data into meta-Analysis. Trials 8, 16, doi: 10.1186/1745-6215-8-16 (2007).